Robert Barrier

609 total citations
20 papers, 447 citations indexed

About

Robert Barrier is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert Barrier has authored 20 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert Barrier's work include Cancer Genomics and Diagnostics (5 papers), Renal cell carcinoma treatment (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Robert Barrier is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Renal cell carcinoma treatment (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Robert Barrier collaborates with scholars based in United States and Türkiye. Robert Barrier's co-authors include Lloyd J. Edwards, Diana O. Perkins, Joyce B. Harp, Jeffrey A. Lieberman, Karen A. Graham, Susan Halabi, Eric J. Small, Edward C. Halperin, Walter M. Stadler and Keith L. Miller and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Psychiatry.

In The Last Decade

Robert Barrier

18 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Barrier United States 10 140 83 83 80 71 20 447
Monica Fujii United States 10 73 0.5× 47 0.6× 51 0.6× 151 1.9× 103 1.5× 28 561
Prasad Bollina United Kingdom 11 231 1.6× 31 0.4× 35 0.4× 76 0.9× 61 0.9× 18 496
Frédéric Balusson France 14 151 1.1× 38 0.5× 14 0.2× 58 0.7× 43 0.6× 38 469
Prasun Subedi United States 10 97 0.7× 35 0.4× 36 0.4× 80 1.0× 60 0.8× 22 434
Katherine Johansen Taber United States 14 173 1.2× 40 0.5× 23 0.3× 66 0.8× 162 2.3× 31 1.1k
Ravi Potluri United States 13 77 0.6× 79 1.0× 64 0.8× 300 3.8× 196 2.8× 77 774
Patricia Bricmont United States 16 275 2.0× 13 0.2× 159 1.9× 109 1.4× 231 3.3× 18 665
Wai Hoong Chang United Kingdom 13 93 0.7× 34 0.4× 22 0.3× 130 1.6× 200 2.8× 24 584
Randy V. Heysek United States 11 242 1.7× 18 0.2× 15 0.2× 232 2.9× 88 1.2× 20 569
Joanna Leadbetter Australia 7 121 0.9× 16 0.2× 84 1.0× 105 1.3× 93 1.3× 14 438

Countries citing papers authored by Robert Barrier

Since Specialization
Citations

This map shows the geographic impact of Robert Barrier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Barrier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Barrier more than expected).

Fields of papers citing papers by Robert Barrier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Barrier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Barrier. The network helps show where Robert Barrier may publish in the future.

Co-authorship network of co-authors of Robert Barrier

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Barrier. A scholar is included among the top collaborators of Robert Barrier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Barrier. Robert Barrier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stadler, Walter M., Susan Halabi, Brian I. Rini, et al.. (2006). A phase II study of gemcitabine and capecitabine in metastatic renal cancer. Cancer. 107(6). 1273–1279. 49 indexed citations
2.
Rini, Brian I., Susan Halabi, Robert Barrier, et al.. (2006). Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. Biology of Blood and Marrow Transplantation. 12(7). 778–785. 27 indexed citations
3.
Ivanova, Anastasia, Robert Barrier, & Vance W. Berger. (2005). Adjusting for observable selection bias in block randomized trials. Statistics in Medicine. 24(10). 1537–1546. 12 indexed citations
4.
5.
Govindan, Ramaswamy, et al.. (2005). A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104. Journal of Clinical Oncology. 23(16_suppl). 7161–7161. 1 indexed citations
6.
Teziç, Tahsin, et al.. (2004). Obesity and Type 2 Diabetes Mellitus: A Population-based Study of Adolescents. Journal of Pediatric Endocrinology and Metabolism. 17(12). 1633–40. 24 indexed citations
7.
Graham, Karen A., Diana O. Perkins, Lloyd J. Edwards, et al.. (2004). Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis. American Journal of Psychiatry. 162(1). 118–123. 120 indexed citations
8.
Halperin, Edward C., et al.. (2004). A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. International Journal of Radiation Oncology*Biology*Physics. 59(5). 1477–1483. 45 indexed citations
9.
Halabi, Susan, Eric J. Small, Nicholas J. Vogelzang, et al.. (2004). Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology. 64(2). 212–217. 27 indexed citations
10.
Stadler, Walter M., Susan Halabi, Marc S. Ernstoff, et al.. (2004). A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. Journal of Clinical Oncology. 22(14_suppl). 4515–4515. 3 indexed citations
11.
Talbot, Jeffrey T., David A. Rizzieri, Robert Barrier, et al.. (2004). Dose-Intense Cyclophosphamide and Etoposide for Patients with Refractory or High-Risk Non-Hodgkin's Lymphoma. Clinical Lymphoma. 5(2). 116–122.
12.
Hobeika, Amy, Michael A. Morse, Takuya Osada, et al.. (2004). Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood. Journal of Immunotherapy. 28(1). 63–72. 64 indexed citations
13.
Stadler, Walter M., Susan Halabi, Marc S. Ernstoff, et al.. (2004). A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. Journal of Clinical Oncology. 22(14_suppl). 4515–4515. 10 indexed citations
14.
15.
Rini, Brian I., Susan Halabi, Robert Barrier, et al.. (2004). CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. Blood. 104(11). 810–810. 1 indexed citations
16.
Miller, Keith L., S. Zhou, Robert Barrier, et al.. (2003). Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. International Journal of Radiation Oncology*Biology*Physics. 56(3). 611–615. 50 indexed citations
17.
Graham, Karen A., Diana O. Perkins, Joyce B. Harp, et al.. (2003). Investigation of olanzapine-associated weight gain in first episode subjects. Schizophrenia Research. 60(1). 355–356. 1 indexed citations
18.
Miller, Keith L., Lawrence B. Marks, Robert Barrier, et al.. (2003). Increased Sectioning of Pathologic Specimens with Ductal Carcinoma In Situ of the Breast: Are There Clinical Consequences?. Clinical Breast Cancer. 4(3). 198–202. 2 indexed citations
19.
Miller, Keith L., Lawrence B. Marks, Robert Barrier, et al.. (2003). Increased Sectioning of Pathologic Specimens with Ductal Carcinoma In Situ of the Breast: Are There Clinical Consequences?. Clinical Breast Cancer. 4(3). 198–202. 1 indexed citations
20.
Barrier, Robert, et al.. (1983). Evaluation of a Public Library's Health Information Service. Medical Reference Services Quarterly. 2(2). 31–51. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monica Fujii Breakdown of academic impact, for papers by Prasad Bollina Breakdown of academic impact, for papers by Frédéric Balusson Breakdown of academic impact, for papers by Prasun Subedi Breakdown of academic impact, for papers by Katherine Johansen Taber Breakdown of academic impact, for papers by Ravi Potluri Breakdown of academic impact, for papers by Patricia Bricmont Breakdown of academic impact, for papers by Wai Hoong Chang Breakdown of academic impact, for papers by Randy V. Heysek Breakdown of academic impact, for papers by Joanna Leadbetter
Rankless by CCL
2026